Neurodegenerative-focused start-up NeuroBo goes public through reverse merge with Gemphire
Gemphire Therapeutics Inc. (therapies for dyslipidemia and nonalcoholic fatty liver disease (NASH)) and private neurodegenerative disease start-up NeuroBo Pharmaceuticals Inc. agreed to an all-stock merger that will result in NeuroBo owning approximately 95.94% of the combined company, which will keep the NeuroBo name and business focus and take over Gemphire's Nasdaq listing with a new ticker symbol.
- Acquisition of Private Biotech
- Full Acquisition
- Includes Contract
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Stock
- Reverse Acquisition
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.